Please assess the completion status of the following clinical trial:

Trial Title: IL2 Imaging in Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Has signed informed consent.~2. ≥18 years of age.~3. Histologically confirmed cutaneous metastatic melanoma (Stage IV).~4. Evidence of at least one measurable metastatic lesion based on RECIST version 1.1.~5. At least one easy accessible metastatic melanoma lesion, of which biopsy can be performed.~6. Eligible for treatment with ipilimumab, nivolumab, pembrolizumab, or the combination of ipilimumab and nivolumab.~7. No contraindication for performing a CT scan.~8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~9. Women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.~10. Must have adequate organ function (e.g. liver, kidney) as defined~Exclusion Criteria:~1. Pre-existing auto-immune disease, which could be exacerbated by ipilimumab (e.g. Crohn, Hashimoto's Thyroiditis).~2. Presence of malignancy other than the disease under study within 5 years of study enrolment. Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~3. Brain metastases that are symptomatic or not stable for 8 weeks (must be documented by imaging).~4. The use of corticosteroids (at the start of treatment). Note: Corticosteroids are allowed during the study for immune-related toxicity of immunotherapy, as this will not interfere with activity of immunotherapy.~5. Evidence of active infection requiring antibiotic therapy at start of treatment.~6. Current use of a prohibited medication or requirement of any of these medications during treatment with immune-checkpoint inhibitors as mentioned in the summary of product characteristics (SPC) for Yervoy, Opdivo, and Keytruda.~7. Known immediate or delayed hypersensitivity reaction to ipilimumab, nivolumab or pembrolizumab or excipients.~8. Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Grade 2 or higher from previous anti-cancer therapy, except alopecia.~9. A history or evidence of cardiovascular risk including any of the following:~   1. A history or evidence of current clinically significant uncontrolled arrhythmias;~  2. A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.~  3. A history or evidence of current ≥Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines.~  4. Abnormal cardiac valve morphology (≥grade 2) documented by echocardiogram (subjects with grade 1 abnormalities \[i.e., mild regurgitation/stenosis\] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.~  5. Presence of cardiac metastases.~10. Any serious or unstable pre-existing medical conditions (i.e. diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol.~11. Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.~12. Pregnant or nursing females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IL2-PET scan (Type: EXPERIMENTAL): \[18F\]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue

Based on this trial design, predict the completion outcome and termination type (if applicable).